Psychotic Disorder Treatment Demand Highest in Europe Holds 25.4% of Global Share

The market for treating psychotic disorders is currently valued at US$ 13.6 billion, but by the end of 2032, it is expected to surpass US$ 24.5 billion. Over the past few years, the general population’s stress levels have significantly increased, which has increased the prevalence of psychotic diseases including bipolar disorder, schizophrenia, etc. According to Fact.MR, the global market for treating psychotic disorders will grow at a high CAGR of 6.1% between 2022 and 2032.

Request for Sample here –

Why Demand for Psychotic Disorder Treatment Highest in Europe?

In 2022, the market for treating psychotic disorders in Europe is expected to be worth $3.45 billion, with a significant market share of 25.4% in the overall industry.

In this region, the prevalence of severe psychotic diseases is rising, and people are becoming more conscious of mental health difficulties.

It is projected that increasing rates of serious mental disorders and more attention to mental health in North America will predominantly drive up demand for psychotic disorder treatment in this region. Currently, the market in the region has a market share of 21.3% and sales of US$ 2.89 billion.

Key Companies Profiled

  • Teva Pharmaceutical Industries Ltd.
  • Amgen Inc.
  • Pfizer Inc.
  • Novartis International AG
  • Merck & Co. Inc.
  • Sanofi S.A.
  • Allergan Plc
  • Mylan N.V.
  • Johnson & Johnson Services Inc.
  • F. Hoffmann-La Roche Ltd

A short viewpoint offered in the report elucidates the macro-economic aspects that influence the growth drivers of Psychotic Disorder Treatment, which includes global GDP of Psychotic Disorder Treatment growth rate, various industries growth rate, such as cosmetics, pharmaceuticals, food and others.

This analysis allows users to evaluate the Psychotic Disorder Treatment market based on a variety of parameters, including scale savings, switching costs, brand loyalty, existing distribution channels, investment in equity, manufacturing and patent rights, government regulations, advertising impact, and consumer preference impacts. All these summary statistics are expected to aid important policymakers in the decision-making process.

Key Highlights of this Report:

  • Industry structure and estimations over the prediction period.
  • Past insights and forecasts.
  • Psychotic Disorder Treatment Market developments and trends are discussed.
  • Regional, sub-regional, and national market scenarios.
  • Psychotic Disorder Treatment Market share, SWOT analysis, product specifications, and competitive landscape are all included in the report.
  • The study also covers government policies as well as macro and microeconomic variables.

This newly published and insightful report compounds sheds light on key dynamics, Key Trends of Psychotic Disorder Treatment and their impact on the overall value chain from Psychotic Disorder Treatment to end-users, which are expected to transform the future of the Psychotic Disorder Treatment sales.

Request for Customization here –

In addition, the study also responds to the pressing topic of whether or not new entrants enter the Psychotic Disorder Treatment market. The research also includes data for the segment, including type, channel segment, industry sector, etc., covering both volume and value of the different segments of the market. Customer information is also covered in numerous industries, which is highly essential to manufacturers.

This research studies the global and major regional Psychotic Disorder Treatment market status and outlook from the perspectives of players, countries, product types, and end industries; this report analyses the top players in the global market and splits the market by product type and applications/end industries. Furthermore, the research recommends a market entrance strategy for new market entrants.

 Psychotic Disorder Treatment Market: Segmentation

  • By Drug Type :
    • Atypical Antipsychotics
    • Phenothiazine Antipsychotics
    • Thioxanthenes
    • Miscellaneous Antipsychotics Agents
  • By Indication :
    • Schizophrenia
    • Bipolar Disorder
    • Delusional Disorder
    • Drug Induced Psychosis
    • Organic Psychosis
  • By Distribution Channel :
    • Hospital Pharmacies
    • Retail Pharmacies
    • Drug Store
    • e-Commerce

Get Full Access of Complete Report:

Key Questions Covered in the Psychotic Disorder Treatment Market Report

  • What will be the estimated size of the Psychotic Disorder Treatment Market in 2023?
  • At what rate will sales in the global Psychotic Disorder Treatment Market grow until 2032?
  • Which are the factors hampering the Psychotic Disorder Treatment and in the artificial sweetener market?
  • Which region will spearhead the growth in the global Psychotic Disorder Treatment Market during 2022-2032?
  • Which are the factors driving sales in the Psychotic Disorder Treatment Market during the forecast period?

Check out more related studies published by Fact.MR Research:

US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583, +353-1-4434-232



Psychotic Disorder Treatment Market is Projected to Surge Past a Valuation of US$ 24.5 Bn by 2032

The global Psychotic Disorder Treatment market is bound to be valued US$ 13.6 Bn in 2022 and have a CAGR of 6.1% between 2022 and 2032.

The Europe psychotic disorder treatment market accounts for a total valuation of US$ 3.45 billion in 2022 and holds a notable market share of 25.4% in the global industry landscape.

Stress levels among the general population have increased notably over the past few years and this has led to an increase in the incidence of psychotic disorders such as bipolar disorder, schizophrenia, etc.

Changes in lifestyle, the prevalence of stress-inducing global and economic conditions, high-stress environments, early onset of mental disorders in teenagers, and increasing prevalence of depression are other factors that could drive demand for psychotic disorder treatment equipment and drugs across the forecast period.

For more insights into the Market, Get A Sample of this Report!

Key Takeaways from Market Study

  • North America holds 21.3% of the overall psychotic disorder treatment market.
  • Europe accounts for a quarter of the psychotic disorder treatment market.
  • The psychotic disorder treatment market is expected to reach US$ 24.58 Bn by the year 2032.
  • Second generation psychotic disorder treatment to dominate the market due to majority of treatment options belonging to this category.

Market Developments

The key participants in psychotic disorder treatment market include H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd., Janssen Pharmaceuticals, Inc., Eli Lilly and Company, Allergan (AbbVie, Inc.), Teva Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Sumitomo Dainippon Pharma Co., Ltd., Alkermes plc, and Bristol-Myers Squibb Company.

  • Alkermes plc, in February 2022, did receive positive results through ENLIGHTEN-Early. It comes across as a phase-III study assessing effect of olanzapine and samidorphan (LYBALVI) in comparison with olanzapine on the body weight, especially in patients aged between 16 and 39 with schizophrenia, bipolar I disorder or schizophreniform disorder.
  • BioXcel Therapeutics, in April 2022, announced that its IGALMI (dexmedetomine) Sublingual Film was approved by the US FDA for treating bipolar disorder.
  • AbbVie, in February 2022, announced submission of a Supplemental New Drug Application to the US FDA. It’s based on the results of new trial for cariprazine (VRAYLAR) to adjunctively treat MDD (major depressive disorder).
  • Otsuka America Pharmaceutical, Inc., along with H. Lundbeck A/S, did receive approval from the US FDAfor supplemental novel drug application, better known as sNDA of REXULTI (brexpiprazole) to treat schizophrenia in patients aged between 13 and 17.
  • Reddy’s Laboratories Ltd., in February 2021, did launch Fluphenazine Hydrochloride tablets known as “USP”. They are actually a generic form of Proxilin tablets (1 mg, 2.5 mg, 5 mg, and 10 mg) by the US FDA.

Connect to an Expert –

Key Benefits for Stakeholders

  • The study provides an in-depth analysis of the psychotic disorder market, and the current trends and future estimations to elucidate the imminent investment pockets.
  • It presents a quantitative analysis of the market from 2021 to 2030 to enable stakeholders to capitalize on the prevailing psychotic disorder market opportunities.
  • Extensive analysis of the market based on procedures and services assists to understand the trends in the industry.
  • Key players and their strategies are thoroughly analyzed to understand the competitive outlook of the psychotic disorder market.

Segmentation of Psychotic Disorder Treatment Industry Research

  • Psychotic Disorder Treatment Market by Drug Type :
    • Atypical Antipsychotics
    • Phenothiazine Antipsychotics
    • Thioxanthenes
    • Miscellaneous Antipsychotics Agents
  • Psychotic Disorder Treatment Market by Indication :
    • Schizophrenia
    • Bipolar Disorder
    • Delusional Disorder
    • Drug Induced Psychosis
    • Organic Psychosis
  • Psychotic Disorder Treatment Market by Distribution Channel :
    • Hospital Pharmacies
    • Retail Pharmacies
    • Drug Store
    • e-Commerce
  • Psychotic Disorder Treatment Market by Region :
    • North America
    • Latin America
    • Europe
    • APAC
    • MEA

Get Full Access of this Report through our PayPal Payment Gateway

About Us:

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.

Contact Us:
21st floor , 136 Sejong-daero,
South Korea
Phone: +1 (628) 251-1583